{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-117809","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.937535+00:00","generated_at":"2026-05-21T23:39:46.279816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling","bullets":["Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.","Cash, equivalents and marketable securities $425.4M at March 31, down from $454.7M at Dec 31.","Phase 3 C-BEYOND HCV trial enrolling; second Phase 3 C-FORWARD expected mid-2025.","Strategic alternatives review with Evercore ongoing; workforce reduced ~25% to save ~$15M through 2027.","Board authorized $25M share repurchase; Arthur Kirsch and Howard Berman appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-117809","json":"https://secwatch.observer/filing/0001193125-25-117809.json","markdown":"https://secwatch.observer/filing/0001193125-25-117809.md","text":"https://secwatch.observer/filing/0001193125-25-117809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/0001193125-25-117809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/d923851d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:39:46.279816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}